New hope for kids with aggressive nerve cancer: immune-boosting combo trial opens

NCT ID NCT07375563

Recruiting now Disease control Sponsor: Federal Research Institute of Pediatric Hematology, Oncology and Immunology Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 3 trial tests a powerful mix of chemotherapy, immunotherapy, and the child's own natural killer (NK) cells for children aged 1.5 to 18 with high-risk neuroblastoma that didn't respond or came back. The goal is to shrink tumors and improve survival by helping the immune system attack cancer more effectively. Only 5 participants will be enrolled at a single center in Russia.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GANGLIONEUROBLASTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ganglioneuroblastoma neuroblastoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GANGLIONEUROBLASTOMA NEUROBLASTOMA (NB)

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

National medical research center of pediatric haematology, oncology and immulogy named after Dmytriy Rogachyov, Moscow, 117198
RECRUITING

Moscow, 117198, Russia

Contact Phone: •••-•••-•••• Email: •••••@•••••